The novel coronavirus (2019-nCoV) is a new strain of coronavirus that had not previously been identified in humans. The coronavirus family is known to cause illness in humans, from common cold to more severe or even fatal diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). There are currently no authorised vaccines or treatments in the EU to prevent or treat novel coronavirus disease (COVID-19) specifically or any other coronaviruses.
As a network of the National Competent Authorities (NCAs) in the EU, the HMA are cooperating together with EMA and the European Commission and to fight the outbreak of the novel coronavirus disease (COVID-19).
All NCAs support the development and approval of vaccines and treatments for novel coronavirus, together with other regulators in the European Union (EU) and worldwide. The NCAs are also engaged in guaranteeing the availability of medicines products to the patients.
HMA, EMA and the European Commission developed a guidance for clinical-trial sponsors on how they should adjust the management of clinical trials and participants during the COVID-19 pandemic which was published on the EMA website.
HMA welcomes the launch of large clinical trials to test promising treatments and to generate conclusive evidence.
Guidance is also available on the actions that sponsors of affected clinical trials should take to help ensure the integrity of their studies and the interpretation of the study results while safeguarding the safety of trial participants as a first priority:
Related HMA contents on clinical trials
HMA strongly supports compassionate use programmes across Europe when treating COVID-19 patients who are not eligible for inclusion in clinical trials. EMA’s human medicines committee (CHMP) gave recommendations on how the investigational antiviral medicine remdesivir should be used in. These recommendations aim to ensure a harmonised approach across EU Member States. They also explain which group of patients may benefit from treatment and provide preliminary information on the medicine’s safety.
Related HMA contents on compassionate use
- Compassionate Use Programmes (from the HMA subgroup on Timely Access)
The document gives an overview of the situation in the different Member States and makes references to the information published on the websites of the NCAs regarding compassionate use programmes and named patient programmes.
Together with the partners in the European medicines regulatory network, such as the European Medicines Agency and the European Commission, HMA has organized the first meeting of the “EU Executive Steering Group on shortages of medicines caused by major events” to discuss measures aimed at addressing the impact of the outbreak of COVID-19 on the supply of medicines in the EU.
- EMA press release on measures taken to address the potential impact of novel coronavirus disease (COVID-19) on medicines supply in the EU
Related HMA contents on shortages
- Availability of Medicines for Human Use
The page includes links to the latest information on shortages for each Member State (where applicable).